Anticoagulant, Cerebrovascular Stroke, Intracranial Hemorrhages, Matrix Metalloproteinases
Conditions
Brief summary
This study was aimed at patients with newly diagnosed stroke / TIA associated with nonvalvular atrial fibrillation. We will observe the effect of early using rivaroxaban anticoagulation on hemorrhagic transformation, and explore the predictive value of multi-mode MRI infarct volume / MMP-9 on hemorrhagic transformation after anticoagulation therapy.
Interventions
DRUGRivaroxaban
new oral anticoagulant molecules which is the selective factor Xa inhibitor
Sponsors
Bayer
Taizhou Hospital
Zhuji People's hospital
Shaoxing People's Hospital
Jinhua Central Hospital
HaiyanPeople's hospital
Wenzhou Central Hospital
The Central Hospital of Lishui City
Dongyang People's Hospital
The Third Affiliated Hospital of Wenzhou Medical University
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female, age≥18; 2. Were newly diagnosed asischemic stroke/TIA concomitant NVAF; 3. Prescribedand accept Rivaroxaban; 4. Sign thewritten informed consent.
Exclusion criteria
1. Renal impairment (CrCl\<15 ml/min) or severe hepatic impairment. 2. Significant hemorrhagic transformation (parenchymal hematoma type I or type II by the ECASS definition). 3. Stroke or TIA caused by large artery atherosclerosis 4. Planned major surgery or invasive intervention 5. Active internal bleeding 6. Malignancy or other serious medical conditions with a life expectancy \<6 months 7. Allergery to Rivaroxaban 8. Pregnancy or breast-feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Susceptibility weighted imaging(SWI) detection of newly developed hemorrhagic transformation after 14 days of rivaroxaban treatment | 14 days after enrolling |
Countries
China
Contacts
Primary ContactMin Lou, PhD
Outcome results
None listed